BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National
Medical Products Administration (NMPA) has approved XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in patients with
multiple
Post Views: 159

PREVIOUS ARTICLE

Dow Jones, Nasdaq, S&P 500: Optimismus an der Wall Street – Technologiewerte haben die Nase vorne

NEXT ARTICLE

Nxt-Id, Inc. to Adjourn Annual Meeting of Stockholders

Related Post

Dow Jones, Nasdaq, S&P 500: US-Anleger warten auf Protokolle der US-Notenbank – Anleger kaufen Aktien von Kreuzfahrt-Betreibern

Dow Jones, Nasdaq, S&P 500: US-Anleger warten auf Protokolle der US-Notenbank – Anleger kaufen Aktien von Kreuzfahrt-Betreibern
/ Apr 7
SRAC CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Stable Road Acquisition Corp.

SRAC CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Stable Road Acquisition Corp.
/ Jul 23
Wall Street: Hohe US-Inflation lässt US-Börsen abrutschen – Techwerte unter Verkaufsdruck

Wall Street: Hohe US-Inflation lässt US-Börsen abrutschen – Techwerte unter Verkaufsdruck
/ Jun 10